Technical Analysis for NTLA - Intellia Therapeutics, Inc.

Grade Last Price % Change Price Change
B 132.37 -1.22% -1.63
NTLA closed down 1.22 percent on Tuesday, July 27, 2021, on 43 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Earnings due: Aug 4
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical NTLA trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Doji - Bullish? Reversal 0.00%
Stochastic Reached Oversold Weakness 0.00%
Multiple of Ten Bullish Other 0.00%
Strong but Oversold Other 0.00%
Strong, Oversold and Reversal Signs Reversal 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Older End-of-Day Signals for NTLA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 9 hours ago
Possible NR7 about 10 hours ago
Lower Bollinger Band Support about 12 hours ago
60 Minute Opening Range Breakdown about 13 hours ago
Down 5% about 13 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Intellia Therapeutics, Inc. Description

Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. It has a strategic collaboration and license agreement with Novartis focused on the development of new ex vivo CRISPR/Cas9-based therapies. Intellia Therapeutics Inc. was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biology Immune System Emerging Technologies Genetics Molecular Biology Hepatitis B Metabolism Precision Medicine Amyloid Liver Disease Hematopoietic Stem Cell Hepatitis B Virus Amyloidosis Chimeric Antigen Receptor Chimeric Antigen Receptor T Cell Liver Diseases Antitrypsin Deficiency Cell Product CRISPR Genome Editing Inborn Errors Of Metabolism Transthyretin Cas9 Transthyretin Amyloidosis

Is NTLA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 202.73
52 Week Low 16.6
Average Volume 2,515,366
200-Day Moving Average 69.14
50-Day Moving Average 105.59
20-Day Moving Average 147.24
10-Day Moving Average 140.42
Average True Range 11.10
ADX 37.82
+DI 28.70
-DI 23.89
Chandelier Exit (Long, 3 ATRs) 169.42
Chandelier Exit (Short, 3 ATRs) 118.19
Upper Bollinger Bands 167.45
Lower Bollinger Band 127.02
Percent B (%b) 0.13
BandWidth 27.46
MACD Line 8.65
MACD Signal Line 12.57
MACD Histogram -3.916
Fundamentals Value
Market Cap 7.82 Billion
Num Shares 59.1 Million
EPS -2.00
Price-to-Earnings (P/E) Ratio -66.05
Price-to-Sales 36.49
Price-to-Book 7.69
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 146.50
Resistance 3 (R3) 145.85 140.48 144.14
Resistance 2 (R2) 140.48 136.88 140.81 143.36
Resistance 1 (R1) 136.43 134.66 133.74 137.08 142.57
Pivot Point 131.06 131.06 129.72 131.39 131.06
Support 1 (S1) 127.01 127.46 124.33 127.66 122.17
Support 2 (S2) 121.64 125.24 121.97 121.38
Support 3 (S3) 117.59 121.64 120.60
Support 4 (S4) 118.24